poisar

Stocks · News reference

Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study

BenzingaVandana Singh

Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading